The anti-allergy medicine market size has grown strongly in recent years. It will grow from $38.84 billion in 2024 to $42.25 billion in 2025 at a compound annual growth rate (CAGR) of 8.8%. This growth during the historic period can be credited to the increasing number of allergic conditions, heightened public awareness about allergy management, wider availability of over-the-counter allergy remedies, better access to healthcare services, and advancements in allergy diagnostic tools.
The anti-allergy medicine market size is expected to see strong growth in the next few years. It will grow to $58.47 billion in 2029 at a compound annual growth rate (CAGR) of 8.5%. Factors driving future growth include a rising global allergy burden, growing preference for rapid-relief medications, an aging population prone to allergies, the proliferation of e-pharmacy platforms, and enhanced governmental support for allergy education. Key trends expected in the market include innovations in drug delivery technologies, the emergence of non-drowsy antihistamines, advancements in customized allergy treatments, expanded R&D in biologic therapies, and the use of digital tools for managing allergic conditions.
The increasing prevalence of allergies is anticipated to drive the growth of the anti-allergy medicine market. Allergies are hypersensitive immune responses to allergens such as pollen, dust mites, certain foods, or pet dander, and can cause symptoms ranging from mild irritation to severe, potentially life-threatening reactions. These include hay fever, asthma, eczema, food allergies, and allergic rhinitis. The rise in allergy cases is largely attributed to growing environmental pollution, which can weaken the immune system and increase sensitivity to common allergens. Anti-allergy medicines provide targeted relief from these allergens, making them essential for managing conditions like hay fever, asthma, and eczema. These medications work by blocking histamines and other triggers, reducing immune overreactions and enhancing daily comfort and quality of life. For example, in November 2024, the Centers for Disease Control and Prevention reported that the number of people with asthma in the United States increased from 24,963,874 in 2021 to 26,799,588 in 2022. This rise in asthma cases underscores the expanding need for effective allergy treatments and supports the growth of the anti-allergy medicine market.
Key players in the anti-allergy medicine market are concentrating on the development of innovative therapies and obtaining regulatory approvals, such as monoclonal antibody treatments, to offer more targeted care, enhance treatment outcomes, reduce side effects, and address severe allergic conditions. Monoclonal antibody therapies are laboratory-engineered proteins designed to mimic the immune system’s function by targeting and blocking specific immune pathways involved in allergic responses. This provides more precise and sustained symptom relief. For instance, in December 2024, Galderma SA, a pharmaceutical company based in Switzerland, received FDA approval for Nemluvio (nemolizumab-ilto) to treat adults and children aged 12 and older with moderate to severe atopic dermatitis. Used in combination with topical corticosteroids or calcineurin inhibitors, this monoclonal antibody acts as an interleukin-31 receptor antagonist, blocking IL-31 signaling - an important factor in inflammation and itching associated with atopic dermatitis - thereby helping improve skin condition and reduce symptoms.
In January 2024, Johnson & Johnson, a US-based pharmaceutical company, acquired Proteologix Inc. for $850 million. This acquisition was intended to bolster Johnson & Johnson’s immunology portfolio by incorporating Proteologix’s bispecific antibody programs, which are being developed to treat immune-mediated diseases such as atopic dermatitis and asthma. Proteologix Inc. is a biotechnology company in the United States that focuses on anti-allergy treatments using novel bispecific antibody therapies to target conditions like asthma and atopic dermatitis.
Major players in the anti-allergy medicine market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., Bayer AG, Sanofi S.A., AstraZeneca plc, Novartis AG, GSK plc, Amgen Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Perrigo Company plc, Cipla Limited, Dr. Reddy's Laboratories, Lupin Limited, Zydus Lifesciences Limited, Takeda Pharmaceutical Company Limited, Torrent Pharmaceuticals Ltd., ALK-Abelló A/S, Torii Pharmaceutical Co. Ltd., Biomay Aktiengesellschaft, Kaléo Inc., Immunomic Therapeutics Inc., Circassia Group plc, Sun Pharmaceutical Industries Ltd., Anergis S.A., Aravax Pty Ltd., DBV Technologies S.A., and Desentum Oy.
North America was the largest region in the anti-allergy medicine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in anti-allergy medicine report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the anti-allergy medicine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Anti-allergy medicine encompasses a wide range of pharmaceutical products formulated to prevent or ease symptoms triggered by allergic reactions. These medications work by targeting the immune system's response to allergens such as pollen, dust mites, pet dander, insect bites, specific foods, and drugs. They help alleviate discomfort by addressing symptoms like sneezing, itching, nasal congestion, hives, and watery eyes.
The primary categories of anti-allergy drugs include antihistamines, corticosteroids, decongestants, leukotriene receptor antagonists, mast cell stabilizers, and other related classes. Antihistamines function by blocking the action of histamine, a compound released by the immune system during allergic responses. These are used to manage various allergy types, including seasonal, perennial, food, skin, and insect bite allergies. Based on formulation, these medicines are available as tablets, capsules, syrups, nasal sprays, eye drops, and injectables. Distribution channels include online pharmacies, hospitals, retail pharmacies, clinics, and others, and they cater to diverse end-user groups such as children, adults, the elderly, and pregnant individuals.
The anti-allergy medicine market research report is one of a series of new reports that provides anti-allergy medicine market statistics, including the anti-allergy medicine industry global market size, regional shares, competitors with the anti-allergy medicine market share, detailed anti-allergy medicine market segments, market trends, and opportunities, and any further data you may need to thrive in the anti-allergy medicine industry. These anti-allergy medicine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The anti-allergy medicine market consists of sales of combination therapies, inhalers, nebulizers, auto-injectors, prefilled syringes, and transdermal patches. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The anti-allergy medicine market size is expected to see strong growth in the next few years. It will grow to $58.47 billion in 2029 at a compound annual growth rate (CAGR) of 8.5%. Factors driving future growth include a rising global allergy burden, growing preference for rapid-relief medications, an aging population prone to allergies, the proliferation of e-pharmacy platforms, and enhanced governmental support for allergy education. Key trends expected in the market include innovations in drug delivery technologies, the emergence of non-drowsy antihistamines, advancements in customized allergy treatments, expanded R&D in biologic therapies, and the use of digital tools for managing allergic conditions.
The increasing prevalence of allergies is anticipated to drive the growth of the anti-allergy medicine market. Allergies are hypersensitive immune responses to allergens such as pollen, dust mites, certain foods, or pet dander, and can cause symptoms ranging from mild irritation to severe, potentially life-threatening reactions. These include hay fever, asthma, eczema, food allergies, and allergic rhinitis. The rise in allergy cases is largely attributed to growing environmental pollution, which can weaken the immune system and increase sensitivity to common allergens. Anti-allergy medicines provide targeted relief from these allergens, making them essential for managing conditions like hay fever, asthma, and eczema. These medications work by blocking histamines and other triggers, reducing immune overreactions and enhancing daily comfort and quality of life. For example, in November 2024, the Centers for Disease Control and Prevention reported that the number of people with asthma in the United States increased from 24,963,874 in 2021 to 26,799,588 in 2022. This rise in asthma cases underscores the expanding need for effective allergy treatments and supports the growth of the anti-allergy medicine market.
Key players in the anti-allergy medicine market are concentrating on the development of innovative therapies and obtaining regulatory approvals, such as monoclonal antibody treatments, to offer more targeted care, enhance treatment outcomes, reduce side effects, and address severe allergic conditions. Monoclonal antibody therapies are laboratory-engineered proteins designed to mimic the immune system’s function by targeting and blocking specific immune pathways involved in allergic responses. This provides more precise and sustained symptom relief. For instance, in December 2024, Galderma SA, a pharmaceutical company based in Switzerland, received FDA approval for Nemluvio (nemolizumab-ilto) to treat adults and children aged 12 and older with moderate to severe atopic dermatitis. Used in combination with topical corticosteroids or calcineurin inhibitors, this monoclonal antibody acts as an interleukin-31 receptor antagonist, blocking IL-31 signaling - an important factor in inflammation and itching associated with atopic dermatitis - thereby helping improve skin condition and reduce symptoms.
In January 2024, Johnson & Johnson, a US-based pharmaceutical company, acquired Proteologix Inc. for $850 million. This acquisition was intended to bolster Johnson & Johnson’s immunology portfolio by incorporating Proteologix’s bispecific antibody programs, which are being developed to treat immune-mediated diseases such as atopic dermatitis and asthma. Proteologix Inc. is a biotechnology company in the United States that focuses on anti-allergy treatments using novel bispecific antibody therapies to target conditions like asthma and atopic dermatitis.
Major players in the anti-allergy medicine market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., Bayer AG, Sanofi S.A., AstraZeneca plc, Novartis AG, GSK plc, Amgen Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Perrigo Company plc, Cipla Limited, Dr. Reddy's Laboratories, Lupin Limited, Zydus Lifesciences Limited, Takeda Pharmaceutical Company Limited, Torrent Pharmaceuticals Ltd., ALK-Abelló A/S, Torii Pharmaceutical Co. Ltd., Biomay Aktiengesellschaft, Kaléo Inc., Immunomic Therapeutics Inc., Circassia Group plc, Sun Pharmaceutical Industries Ltd., Anergis S.A., Aravax Pty Ltd., DBV Technologies S.A., and Desentum Oy.
North America was the largest region in the anti-allergy medicine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in anti-allergy medicine report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the anti-allergy medicine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Anti-allergy medicine encompasses a wide range of pharmaceutical products formulated to prevent or ease symptoms triggered by allergic reactions. These medications work by targeting the immune system's response to allergens such as pollen, dust mites, pet dander, insect bites, specific foods, and drugs. They help alleviate discomfort by addressing symptoms like sneezing, itching, nasal congestion, hives, and watery eyes.
The primary categories of anti-allergy drugs include antihistamines, corticosteroids, decongestants, leukotriene receptor antagonists, mast cell stabilizers, and other related classes. Antihistamines function by blocking the action of histamine, a compound released by the immune system during allergic responses. These are used to manage various allergy types, including seasonal, perennial, food, skin, and insect bite allergies. Based on formulation, these medicines are available as tablets, capsules, syrups, nasal sprays, eye drops, and injectables. Distribution channels include online pharmacies, hospitals, retail pharmacies, clinics, and others, and they cater to diverse end-user groups such as children, adults, the elderly, and pregnant individuals.
The anti-allergy medicine market research report is one of a series of new reports that provides anti-allergy medicine market statistics, including the anti-allergy medicine industry global market size, regional shares, competitors with the anti-allergy medicine market share, detailed anti-allergy medicine market segments, market trends, and opportunities, and any further data you may need to thrive in the anti-allergy medicine industry. These anti-allergy medicine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The anti-allergy medicine market consists of sales of combination therapies, inhalers, nebulizers, auto-injectors, prefilled syringes, and transdermal patches. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Anti-Allergy Medicine Market Characteristics3. Anti-Allergy Medicine Market Trends And Strategies4. Anti-Allergy Medicine Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market32. Global Anti-Allergy Medicine Market Competitive Benchmarking And Dashboard33. Key Mergers And Acquisitions In The Anti-Allergy Medicine Market34. Recent Developments In The Anti-Allergy Medicine Market
5. Global Anti-Allergy Medicine Growth Analysis And Strategic Analysis Framework
6. Anti-Allergy Medicine Market Segmentation
7. Anti-Allergy Medicine Market Regional And Country Analysis
8. Asia-Pacific Anti-Allergy Medicine Market
9. China Anti-Allergy Medicine Market
10. India Anti-Allergy Medicine Market
11. Japan Anti-Allergy Medicine Market
12. Australia Anti-Allergy Medicine Market
13. Indonesia Anti-Allergy Medicine Market
14. South Korea Anti-Allergy Medicine Market
15. Western Europe Anti-Allergy Medicine Market
16. UK Anti-Allergy Medicine Market
17. Germany Anti-Allergy Medicine Market
18. France Anti-Allergy Medicine Market
19. Italy Anti-Allergy Medicine Market
20. Spain Anti-Allergy Medicine Market
21. Eastern Europe Anti-Allergy Medicine Market
22. Russia Anti-Allergy Medicine Market
23. North America Anti-Allergy Medicine Market
24. USA Anti-Allergy Medicine Market
25. Canada Anti-Allergy Medicine Market
26. South America Anti-Allergy Medicine Market
27. Brazil Anti-Allergy Medicine Market
28. Middle East Anti-Allergy Medicine Market
29. Africa Anti-Allergy Medicine Market
30. Anti-Allergy Medicine Market Competitive Landscape And Company Profiles
31. Anti-Allergy Medicine Market Other Major And Innovative Companies
35. Anti-Allergy Medicine Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Anti-Allergy Medicine Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on anti-allergy medicine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for anti-allergy medicine ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The anti-allergy medicine market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Drug Class: Antihistamines; Corticosteroids; Decongestants; Leukotriene Inhibitors; Mast Cell Stabilizers; Other Drug Classes2) By Type Of Allergy: Seasonal Allergies; Perennial Allergies; Food Allergies; Skin Allergies; Insect Sting Allergies
3) By Formulation: Tablets; Capsules; Syrups; Nasal Sprays; Eye Drops; Injectables
4) By Application: Online Pharmacy; Hospital; Offline Pharmacy; Clinic; Other Applications
5) By End User: Children; Adults; Geriatric Population; Pregnant Women
Subsegments:
1) By Antihistamines: First-Generation Antihistamines; Second-Generation Antihistamines; Third-Generation Antihistamines2) By Corticosteroids: Oral Corticosteroids; Nasal Corticosteroids; Inhaled Corticosteroids; Topical Corticosteroids
3) By Decongestants: Oral Decongestants; Nasal Spray Decongestants; Topical Decongestants
4) By Leukotriene Inhibitors: Leukotriene Receptor Antagonists; Leukotriene Synthesis Inhibitors
5) By Mast Cell Stabilizers: Cromolyn Sodium; Nedocromil Sodium
6) By Other Drug Classes: Immunotherapy Agents; Biologics; Monoclonal Antibodies
Key Companies Profiled: Pfizer Inc.; Johnson & Johnson; F. Hoffmann-La Roche AG; Merck & Co. Inc.; Bayer AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Pfizer Inc.
- Johnson & Johnson
- F. Hoffmann-La Roche AG
- Merck & Co. Inc.
- Bayer AG
- Sanofi S.A.
- AstraZeneca plc
- Novartis AG
- GSK plc
- Amgen Inc.
- Teva Pharmaceutical Industries Ltd.
- Regeneron Pharmaceuticals Inc.
- Perrigo Company plc
- Cipla Limited
- Dr. Reddy's Laboratories
- Lupin Limited
- Zydus Lifesciences Limited
- Takeda Pharmaceutical Company Limited
- Torrent Pharmaceuticals Ltd.
- ALK-Abelló A/S
- Torii Pharmaceutical Co. Ltd.
- Biomay Aktiengesellschaft
- Kaléo Inc.
- Immunomic Therapeutics Inc.
- Circassia Group plc
- Sun Pharmaceutical Industries Ltd.
- Anergis S.A.
- Aravax Pty Ltd.
- DBV Technologies S.A.
- Desentum Oy.